Lipoprotein(a) Is Associated With Increased Risk of Abdominal Aortic Aneurysm
Lp(a) is a genetically determined lipoprotein targeted by emerging therapies. In a UK Biobank analysis (1,026 abdominal aortic aneurysm [AAA] cases, 469,989 controls), elevated Lp(a) was associated with increased risk of AAA, including at clinically relevant thresholds while controlling for traditional risk factors, including ApoB. Multivariable Mendelian randomization confirmed a causal relationship between lipoprotein(a) [Lp(a)] and AAA independent of apolipoprotein B. These findings support Lp(a) as a modifiable risk factor and potential therapeutic target for AAA, a condition with limited medical treatment options. AAA should be considered as an outcome in future clinical trials of Lp(a)-lowering therapies.
Authors
- Corry Gellatly (ORCID: https://orcid.org/0000-0001-7458-2988)
- Renae Judy (ORCID: https://orcid.org/0000-0003-0915-2222)
- Katie Saxby (ORCID: https://orcid.org/0000-0002-8183-7659)
- Daniel James Rader (ORCID: https://orcid.org/0000-0002-9245-9876)
- Matthew J. Bown (ORCID: https://orcid.org/0000-0002-6180-3611)
- Michael G. Levin (ORCID: https://orcid.org/0000-0002-9937-9932)
- Scott M. Damrauer (ORCID: https://orcid.org/0000-0001-8009-1632)
- Shuai Yuan
- Pranav Sharma
Institutions
- Washington University in St. Louis (US)
- Glenfield Hospital (GB)
- NIHR Leicester Cardiovascular Biomedical Research Unit (GB)
- Philadelphia VA Medical Center (US)
- NIHR Leicester Biomedical Research Centre (GB)
- University of Pennsylvania (US)
Publication Details
- Journal
- JACC Basic to Translational Science
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1016/j.jacbts.2025.101457
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00